Compare Occidental Petroleum Corporation (OXY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Occidental Petroleum Corporation trades at $57.7 (market cap $56.20B), while State Street SPDR S&P Biotech ETF trades at $151.92. The key difference: Occidental Petroleum Corporation pays a 1.84% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Occidental Petroleum Corporation nearer its low. Which is the better fit depends on your goals.
| OXY | XBI | |
|---|---|---|
Market Cap | $56.20B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $66.24 | $164.28 |
52-Week Low | $38.92 | $85.16 |
Enterprise Value | $77.28B | — |
Dividend Yield | 1.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $56.50, up 2.99% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 22.42% net income margin and robust cash flow from operations of $10.53B in 2025. Recent news highlights Permian Basin growth and capital spending cuts, while analyst consensus leans bullish with a $65.38 price target.
OXY presents upside potential driven by earnings momentum and debt reduction, but faces risks from oil price volatility and declining revenue trends. The stock's elevated P/E ratio of 74.58 warrants caution, though institutional support and strategic positioning in carbon capture technology offer long-term value. Current levels near resistance at $57 require monitoring for breakout confirmation.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
